Ignite Creation Date:
2025-12-25 @ 2:22 AM
Ignite Modification Date:
2025-12-26 @ 6:04 AM
Study NCT ID:
NCT01828034
Status:
COMPLETED
Last Update Posted:
2020-11-17
First Post:
2013-04-05
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
First Line Gemcitabine, Cisplatin and MEK162 in Advanced Biliary Tract Carcinoma
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
13-004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |